TRAVERE THERAPEUTICS, INC. Additional Paid in Capital, Common Stock
TRAVERE THERAPEUTICS, INC. (TVTX) had Additional Paid in Capital, Common Stock of $1.02 billion as of 2021-09-30, per its 10-Q filed 2021-10-29.
Discontinued › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2021-10-29
- 2021-09-30: Additional Paid in Capital, Common Stock $1.02B.
- 2021-06-30: Additional Paid in Capital, Common Stock $1.01B.
- 2021-03-31: Additional Paid in Capital, Common Stock $1.00B.
- 2020-12-31: Additional Paid in Capital, Common Stock $797.99M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2021-09-30 | $1.02B 10-Q · filed 2021-10-29 | |
| 2021-06-30 | $1.01B 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $1.00B 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $797.99M 10-Q · filed 2021-10-29 | |
| 2020-09-30 | $765.31M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $758.95M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $642.88M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $636.91M 10-Q · filed 2020-11-05 | |
| 2019-09-30 | $630.97M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $626.00M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $596.64M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $589.79M 10-Q · filed 2019-10-30 | |
| 2018-09-30 | $582.71M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $497.18M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $486.72M 10-Q · filed 2018-07-06 | |
| 2017-12-31 | $471.80M 10-Q · filed 2018-11-01 | |
| 2017-09-30 | $465.15M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $438.64M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $430.37M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $421.31M 10-Q · filed 2017-11-07 | |
| 2016-09-30 | $412.35M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $381.69M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $373.33M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $365.80M 10-Q · filed 2016-11-04 | |
| 2015-09-30 | $353.79M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $318.28M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $310.21M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $140.85M 10-Q · filed 2015-11-06 | $140.85M 10-Q · filed 2015-05-11 |
| 2014-09-30 | $138.41M 10-Q · filed 2014-11-13 | |
| 2013-12-31 | $49.64M 10-K/A · filed 2015-07-09 | $50.19M 10-Q · filed 2014-11-13 |
| 2012-12-31 | $30.20M 10-K/A · filed 2015-07-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |